TH027
/ ThinkingBiomed
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 23, 2026
An Open-Label, Dose-Escalation, Multiple Administration, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Anti-tumor Activity of TH-CART-027 Cell Injection in Subjects with Recurrent or Progressive Grade 4 Glioma
(ChiCTR)
- P=N/A | N=21 | Sponsor: Shanghai Tongji Hospital; Shanghai Tongji Hospital
New trial • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • BRAF • CD276 • NTRK
1 to 1
Of
1
Go to page
1